Jaume Capdevila

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1445694/publications.pdf

Version: 2024-02-01

135	10,725	134610	36203
papers	citations	34 h-index	101 g-index

136	136	136	10315
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study. Neuroendocrinology, 2022, 112, 88-100.	1.2	6
2	Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. Oncologist, 2022, 27, e328-e339.	1.9	3
3	Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module). Journal of Neuroendocrinology, 2022, 34, e13097.	1.2	5
4	Cervical dissecting extravasation of oxaliplatin: A case report. Molecular and Clinical Oncology, 2022, 16, 60.	0.4	1
5	What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?. Current Oncology Reports, 2022, 24, 451-461.	1.8	1
6	Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treatment Reviews, 2022, 106, 102380.	3.4	26
7	Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer â€“ The RAPIDO trial. Radiotherapy and Oncology, 2022, 171, 69-76.	0.3	20
8	Clinical activity of <scp>CCâ€90011</scp>, an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies. Cancer, 2022, 128, 3185-3195.	2.0	10
9	Cabozantinib versus placebo in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on histology subtypes.. Journal of Clinical Oncology, 2022, 40, 6081-6081.	0.8	1
10	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 438-446.	3.2	21
11	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 29-42.	5.1	739
12	A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.8	20
13	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. European Journal of Cancer, 2021, 144, 200-214.	1.3	12
14	Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clinical Cancer Research, 2021, 27, 2890-2898.	3.2	44
15	Drug Development in Neuroendocrine Tumors: What Is on the Horizon?. Current Treatment Options in Oncology, 2021, 22, 43.	1.3	8
16	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73.	1.3	120
17	Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid, 2021, 31, 1226-1234.	2.4	24
18	Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. Scientific Reports, 2021, 11, 7402.	1.6	1

#	Article	IF	Citations
19	Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?. Current Oncology Reports, 2021, 23, 80.	1.8	1
20	Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor â€" an update on neuroendocrine neoplasmâ€™s treatment: A case report. World Journal of Hepatology, 2021, 13, 611-619.	0.8	0
21	Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. Journal of Clinical Medicine, 2021, 10, 2131.	1.0	13
22	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). Journal of Clinical Oncology, 2021, 39, 2304-2312.	0.8	49
23	Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 1126-1138.	5.1	136
24	1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913). Annals of Oncology, 2021, 32, S908-S909.	0.6	4
25	A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. Molecular Cancer Therapeutics, 2021, 20, 2250-2261.	1.9	11
26	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. Molecular Cancer Therapeutics, 2020, 19, 312-317.	1.9	8
27	Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research, 2020, 26, 902-909.	3.2	29
28	VITAL phase 2 study: Upfront 5â€fluorouracil, mitomycinâ€C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09â€02). Cancer Medicine, 2020, 9, 1008-1016.	1.3	12
29	Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy asÂpreoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long termÂresults. BMC Cancer, 2020, 20, 1164.	1.1	7
30	PD-1 Blockade in Anaplastic Thyroid Carcinoma. Journal of Clinical Oncology, 2020, 38, 2620-2627.	0.8	177
31	Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Annals of Oncology, 2020, 31, 1366-1375.	0.6	80
32	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). Oncologist, 2020, 25, 745-e1265.	1.9	25
33	SEOM clinical guideline thyroid cancer (2019). Clinical and Translational Oncology, 2020, 22, 223-235.	1.2	23
34	Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. Oncologist, 2019, 24, 38-46.	1.9	23
35	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. Journal of Clinical Oncology, 2019, 37, 2571-2580.	0.8	49
36	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). British Journal of Cancer, 2019, 121, 537-544.	2.9	18

#	Article	IF	Citations
37	Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and metaâ€analysis. Head and Neck, 2019, 41, 2823-2829.	0.9	5
38	Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881982821.	1.4	8
39	Metaâ€Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Oncologist, 2019, 24, e1315-e1320.	1.9	8
40	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. Oncologist, 2019, 24, 1375-1383.	1.9	22
41	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). Clinical and Translational Oncology, 2019, 21, 55-63.	1.2	17
42	Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group. Neuroendocrinology, 2019, 108, 5-6.	1.2	8
43	Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology, 2019, 108, 26-36.	1.2	46
44	The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of thecombination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naÃ¯ve forsystemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE).. Journal of Clinical Oncology, 2019, 37, 4105-4105.	0.8	5
45	Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).. Journal of Clinical Oncology, 2019, 37, 4106-4106.	0.8	25
46	Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 2019, 26, 391-403.	1.6	32
47	Early evolutionary divergence between papillary and anaplastic thyroid cancers. Annals of Oncology, 2018, 29, 1454-1460.	0.6	44
48	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 2018, 8, 1445.	1.6	55
49	Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treatment Reviews, 2018, 70, 209-222.	3.4	12
50	Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	18
51	Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clinical and Translational Oncology, 2018, 20, 1522-1528.	1.2	10
52	The right compound for the right target: tackling RET. Annals of Oncology, 2018, 29, 1623-1625.	0.6	5
53	Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. Oncotarget, 2018, 9, 36894-36905.	0.8	9
54	ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology, 2017, 105, 310-319.	1.2	97

#	Article	IF	Citations
55	Analysis of mutant allele fractions in driver genes in colorectal cancer â€“ biological and clinical insights. Molecular Oncology, 2017, 11, 1263-1272.	2.1	26
56	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of Oncology, 2017, 28, 1309-1315.	0.6	82
57	Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Current Oncology Reports, 2017, 19, 72.	1.8	13
58	The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Targeted Oncology, 2017, 12, 757-774.	1.7	1
59	Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). European Journal of Endocrinology, 2017, 177, 309-317.	1.9	30
60	Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. Future Oncology, 2017, 13, 615-624.	1.1	32
61	Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene, 2017, 36, 1899-1907.	2.6	26
62	Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study.. Journal of Clinical Oncology, 2017, 35, 4089-4089.	0.8	9
63	Clinical and molecular determinants of treatment benefit with phase I trials in patients (pts) with advanced pancreatic cancer (PC).. Journal of Clinical Oncology, 2017, 35, 409-409.	0.8	1
64	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opinion on Emerging Drugs, 2016, 21, 267-282.	1.0	7
65	Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4103-4109.	1.8	78
66	Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. Journal of Clinical Oncology, 2016, 34, 3906-3913.	0.8	206
67	Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, e17-e24.	0.8	18
68	ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology, 2016, 103, 172-185.	1.2	844
69	ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2016, 103, 153-171.	1.2	1,074
70	Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocrine-Related Cancer, 2016, 23, 191-199.	1.6	193
71	Clonality patterns of driver mutations (mut) to reveal spatial-temporal genomic heterogeneity in colorectal cancer (CRC).. Journal of Clinical Oncology, 2016, 34, 3509-3509.	0.8	0
72	A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Research, 2016, 36, 713-9.	0.5	66

#	Article	IF	Citations
73	Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer and Metastasis Reviews, 2015, 34, 823-842.	2.7	39
74	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of Oncology, 2015, 26, 1604-1620.	0.6	514
75	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Annals of Oncology, 2015, 26, 1987-1993.	0.6	112
76	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer, 2015, 15, 60.	1.1	41
77	GEPâ€“NETs UPDATE: Biotherapy for neuroendocrine tumours. European Journal of Endocrinology, 2015, 172, R31-R46.	1.9	41
78	Elucidating the molecular aspects of colorectal cancer and their clinical importance. Colorectal Cancer, 2015, 4, 175-183.	0.8	0
79	Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer, 2015, 15, 495.	1.1	25
80	Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer and Metastasis Reviews, 2015, 34, 381-400.	2.7	49
81	A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. Annals of Oncology, 2015, 26, 2085-2091.	0.6	37
82	Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.. Journal of Clinical Oncology, 2015, 33, 4091-4091.	0.8	5
83	Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.. Journal of Clinical Oncology, 2015, 33, e15182-e15182.	0.8	3
84	Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.. Journal of Clinical Oncology, 2015, 33, 233-233.	0.8	4
85	Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study.. Journal of Clinical Oncology, 2015, 33, 367-367.	0.8	2
86	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2015, 33, 581-581.	0.8	1
87	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall dâ€™Hebron Institute of Oncology phase I program cohort.. Journal of Clinical Oncology, 2015, 33, 587-587.	0.8	0
88	Everolimus (Eve) for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (Pnet): Final Overall Survival (Os) Results of a Randomized, Double-Blind, Placebo (Pbo)-Controlled, Multicenter Phase III Trial (Radiant-3). Annals of Oncology, 2014, 25, iv394.	0.6	10
89	Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics: Targets and Therapy, 2014, 8, 129.	3.0	73
90	FcÎ³RIIaandFcÎ³RIIIaPolymorphisms and Cetuximab Benefit in the Microscopic Disease. Clinical Cancer Research, 2014, 20, 4511-4519.	3.2	7

#	Article	IF	Citations
91	RAF signaling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2014, 40, 974-979.	3.4	21
92	Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets. Cancer and Metastasis Reviews, 2014, 33, 345-351.	2.7	29
93	Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2014, 371, 224-233.	13.9	1,460
94	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. European Journal of Cancer, 2014, 50, 496-505.	1.3	26
95	Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.. Journal of Clinical Oncology, 2014, 32, 3562-3562.	0.8	1
96	Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profileâ€"VITAL study, GEMCAD 09-02 clinical trial.. Journal of Clinical Oncology, 2014, 32, 4034-4034.	0.8	2
97	Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).. Journal of Clinical Oncology, 2014, 32, 6027-6027.	0.8	2
98	Correlation of VEGFR2 expression in tumor tissue with longer progression-free survival in patients with neuroendocrine tumors (NETs) treated with pazopanib.. Journal of Clinical Oncology, 2014, 32, e15154-e15154.	0.8	3
99	Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.. Journal of Clinical Oncology, 2014, 32, 465-465.	0.8	2
100	Potential role of mTOR phosphorylation status as a negative predictor to everolimus plus octreotide in NETs.. Journal of Clinical Oncology, 2014, 32, 484-484.	0.8	1
101	Study of the gastroenteropancreatic neuroendocrine tumor (gep-net) microenvironment beyond angiogenesis: The role of lysyl oxidase-like 2 (LOXL2).. Journal of Clinical Oncology, 2014, 32, 4109-4109.	0.8	0
102	Pazopanib activity in pancreatic neuroendocrine tumors (pNETs).. Journal of Clinical Oncology, 2014, 32, e15171-e15171.	0.8	0
103	FCÎ³RIIa and FCÎ³RIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 3573-3573.	0.8	0
104	Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3591-3591.	0.8	0
105	Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC).. Journal of Clinical Oncology, 2014, 32, e17015-e17015.	0.8	0
106	Clinical scenario 1: Advanced, grade 2, neuroendocrine tumor in the midgut. Clinical Advances in Hematology and Oncology, 2014, 12, 17-9.	0.3	2
107	Continued advances in targeting gastroenteropancreatic neuroendocrine tumors: general discussion. Clinical Advances in Hematology and Oncology, 2014, 12, 22; quiz 23.	0.3	1
108	A phase I pharmacokinetic study of PM00104 (ZalypsisÂ®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 1247-1254.	1.1	9

#	Article	IF	Citations
109	sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.. Journal of Clinical Oncology, 2013, 31, 4140-4140.	0.8	17
110	Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody.. Journal of Clinical Oncology, 2013, 31, 379-379.	0.8	0
111	Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) SMARCB1 in NENS of colorectal origin using next-generation sequencing (NGS).. Journal of Clinical Oncology, 2013, 31, 4135-4135.	0.8	0
112	A significant response to sunitinib in a patient with anaplastic thyroid carcinoma. Journal of Research in Medical Sciences, 2013, 18, 623-5.	0.4	17
113	Sorafenib in metastatic thyroid cancer. Endocrine-Related Cancer, 2012, 19, 209-216.	1.6	96
114	Evaluation of CYP3A5, VEGF-a, and VEGFR2 polymorphisms as markers of sunitinib toxicity.. Journal of Clinical Oncology, 2012, 30, 10546-10546.	0.8	2
115	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer.. Journal of Clinical Oncology, 2012, 30, 3571-3571.	0.8	1
116	PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)â€"NCT01280201.. Journal of Clinical Oncology, 2012, 30, 4119-4119.	0.8	7
117	Evaluation of safety and efficacy of somatuline autogel in combination with molecular targeted therapies (MTT) in patients with neuroendocrine tumors (NETs): Data from one Spanish cohort.. Journal of Clinical Oncology, 2012, 30, e14671-e14671.	0.8	2
118	The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.. Journal of Clinical Oncology, 2012, 30, 678-678.	0.8	5
119	Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase I clinical trials.. Journal of Clinical Oncology, 2012, 30, 3014-3014.	0.8	1
120	The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint.. Journal of Clinical Oncology, 2012, 30, TPS10632-TPS10632.	0.8	1
121	The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2012, 30, e14088-e14088.	0.8	0
122	Senescence, a new concept in pathologic response evaluation of rectal carcinomas (RC) after neoadjuvant treatment.. Journal of Clinical Oncology, 2012, 30, e21021-e21021.	0.8	0
123	Everolimus for Advanced Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2011, 364, 514-523.	13.9	2,547
124	Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer and Metastasis Reviews, 2011, 30, 27-34.	2.7	67
125	A Shining Light in the Darkness for the Treatment of Pancreatic Neuroendocrine Tumors. Cancer Discovery, 2011, 1, 213-221.	7.7	26
126	Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Annals of Oncology, 2010, 21, 1794-1803.	0.6	338

#	Article	IF	Citations
127	New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era. Discovery Medicine, 2010, 9, 153-62.	0.5	10
128	The role of salvage treatment in advanced colorectal cancer. Critical Reviews in Oncology/Hematology, 2009, 71, 53-61.	2.0	13
129	Targeted therapies in thyroid cancer. Targeted Oncology, 2009, 4, 275-285.	1.7	2
130	Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Targeted Oncology, 2009, 4, 287-296.	1.7	16
131	Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treatment Reviews, 2009, 35, 354-363.	3.4	120
132	Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. Current Opinion in Oncology, 2009, 21, 374-380.	1.1	3
133	Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 1223-1236.	1.1	34
134	New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. Expert Review of Anticancer Therapy, 2007, 7, 1027-1041.	1.1	3
135	Monoclonal antibodies in the treatment of advanced colorectal cancer. European Journal of Surgical Oncology, 2007, 33, S24-S34.	0.5	16